Advanced

The Effect of Snuff (Smokeless Tobacco) on Disease Activity and Function in Rheumatoid Arthritis: Experiences From the Better Anti-Rheumatic FarmacOTherapy, a Longitudinal Multicenter Study on Early Rheumatoid Arthritis.

Andersson, Maria LU ; Bergman, Stefan LU and Söderlin, Maria LU (2013) In Journal of Clinical Rheumatology 19(1). p.14-18
Abstract
BACKGROUND: It is not known whether snuff (moist smokeless tobacco) affects disease activity in rheumatoid arthritis (RA). OBJECTIVE: This study aims to study the effect of snuff on disease activity and function in Swedish patients with early RA. METHODS: Between 1992 and 2005, 2800 adult patients were included in the Better Anti-Rheumatic FarmacOTherapy (BARFOT) early RA study in Sweden. Disease Activity Score 28 joints (DAS28), Health Assessment Questionnaire, visual analog scale for general health, and drug treatment were registered at inclusion and at follow-up after 1, 2, and 5 years. European League Against Rheumatism response and remission criteria were applied at 1 year. In 2010, a self-completed postal questionnaire was sent to... (More)
BACKGROUND: It is not known whether snuff (moist smokeless tobacco) affects disease activity in rheumatoid arthritis (RA). OBJECTIVE: This study aims to study the effect of snuff on disease activity and function in Swedish patients with early RA. METHODS: Between 1992 and 2005, 2800 adult patients were included in the Better Anti-Rheumatic FarmacOTherapy (BARFOT) early RA study in Sweden. Disease Activity Score 28 joints (DAS28), Health Assessment Questionnaire, visual analog scale for general health, and drug treatment were registered at inclusion and at follow-up after 1, 2, and 5 years. European League Against Rheumatism response and remission criteria were applied at 1 year. In 2010, a self-completed postal questionnaire was sent to 2102 patients in the BARFOT study enquiring about lifestyle factors such as smoking and use of snuff. Three controls for each patient using snuff were identified. RESULTS: Fifty-one patients who used snuff were identified, together with 145 controls. When we adjusted for socioeconomic class, disease duration, and previous antirheumatic medication, the snuff users had lower DAS28 values at up to 6 months of follow-up than patients who had never smoked, and they had lower DAS28 values than previous smokers at up to 2 years of follow-up. No effect of snuff use on European League Against Rheumatism response was seen at up to 1 year. CONCLUSIONS: Snuff users initially had lower DAS28 levels than never smokers and previous smokers. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
smokeless tobacco, rheumatoid arthritis, snuff, epidemiology
in
Journal of Clinical Rheumatology
volume
19
issue
1
pages
14 - 18
publisher
Lippincott Williams & Wilkins
external identifiers
  • wos:000314615500003
  • pmid:23319018
  • scopus:84874187791
ISSN
1536-7355
DOI
10.1097/RHU.0b013e31828214ed
language
English
LU publication?
yes
id
99c6c800-1bb2-4d26-84b2-abb3fc781eaf (old id 3438715)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23319018?dopt=Abstract
date added to LUP
2013-02-04 13:35:47
date last changed
2019-02-20 06:59:43
@article{99c6c800-1bb2-4d26-84b2-abb3fc781eaf,
  abstract     = {BACKGROUND: It is not known whether snuff (moist smokeless tobacco) affects disease activity in rheumatoid arthritis (RA). OBJECTIVE: This study aims to study the effect of snuff on disease activity and function in Swedish patients with early RA. METHODS: Between 1992 and 2005, 2800 adult patients were included in the Better Anti-Rheumatic FarmacOTherapy (BARFOT) early RA study in Sweden. Disease Activity Score 28 joints (DAS28), Health Assessment Questionnaire, visual analog scale for general health, and drug treatment were registered at inclusion and at follow-up after 1, 2, and 5 years. European League Against Rheumatism response and remission criteria were applied at 1 year. In 2010, a self-completed postal questionnaire was sent to 2102 patients in the BARFOT study enquiring about lifestyle factors such as smoking and use of snuff. Three controls for each patient using snuff were identified. RESULTS: Fifty-one patients who used snuff were identified, together with 145 controls. When we adjusted for socioeconomic class, disease duration, and previous antirheumatic medication, the snuff users had lower DAS28 values at up to 6 months of follow-up than patients who had never smoked, and they had lower DAS28 values than previous smokers at up to 2 years of follow-up. No effect of snuff use on European League Against Rheumatism response was seen at up to 1 year. CONCLUSIONS: Snuff users initially had lower DAS28 levels than never smokers and previous smokers.},
  author       = {Andersson, Maria and Bergman, Stefan and Söderlin, Maria},
  issn         = {1536-7355},
  keyword      = {smokeless tobacco,rheumatoid arthritis,snuff,epidemiology},
  language     = {eng},
  number       = {1},
  pages        = {14--18},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {Journal of Clinical Rheumatology},
  title        = {The Effect of Snuff (Smokeless Tobacco) on Disease Activity and Function in Rheumatoid Arthritis: Experiences From the Better Anti-Rheumatic FarmacOTherapy, a Longitudinal Multicenter Study on Early Rheumatoid Arthritis.},
  url          = {http://dx.doi.org/10.1097/RHU.0b013e31828214ed},
  volume       = {19},
  year         = {2013},
}